Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corin's strong H1 top-line eclipsed by expected Cormet slowdown

This article was originally published in Clinica

Executive Summary

UK orthopaedic firm Corin said revenues for the first half of 2008 jumped 63% to £22.9m ($41m) to reflect the initial roll-out of its Cormet hip resurfacing system in the US by heavyweight distribution partner Stryker. This significant lift in the company's top-line gave a 55% boost to pre-tax profit, which reached £1.8m. These strong results, however, were marred by the company's previous announcement in May that Stryker was not restocking its inventory of the hip implant until the end of the year as it anticipates a slowdown in Cormet procedures (see Clinica No 1307, p 3). While this has led to Corin slashing its 2008 revenue outlook, the Cirencester-based company said it "remained confident of Cormet's success in the US, although over a longer time frame than previously anticipated".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel